Nexmed (Holdings) Incorporated

The Children's Hospital of Philadelphia

Mezzion Pharma Co., Ltd.

Achelios Therapeutics, Inc.

Exodos Life Sciences LP

Centric Research Institute

Innovus Pharmaceuticals, Inc.

James L Yeager

Servet Buyuktimkin

Nadir Buyuktimkin

Y Joseph Mo

Mingqi Lu

Qin Wang

David J Goldberg

Stephen M Paridon

Albert Liu

Servet B&uuml;y&uuml;ktimkin

Nadir B&uuml;y&uuml;ktimkin

Nadir Büyüktimkin

Servet Büyüktimkin

Joseph Y Mo

The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.

Methods of improving myocardial performance in Fontan patients using udenafil compositions

A topical composition includes a non-steroidal anti-inflammatory drug (NSAID) in an aqueous carrier system which contains a cationic galactomannan gum. The carrier system includes, in addition to water and the cationic galactomannan gum, a lactate ester of a Cto Csaturated aliphatic alcohol, a monoprotic arylalkanoic acid (pKa 3.8 to 5), a solubility enhancer, and a Cto Csaturated aliphatic alcohol.

Topical anti-inflammatory compositions

Aqueous, topical compositions contain an allylamine or an azole as an antifungal agent together with a lactate ester, an organic acid (pKa 3.8-5), ethanol, water, and a cationic galactomannan gum.

Topical antifungal compositions

Aqueous, topical antifungal compositions contain an allylamine or an azole as the antifungal agent together with a lactate ester, an organic acid (pKa 3.8-5), a Cto Csaturated aliphatic alcohol, and a cationic galactomannan gum.

Methods of improving myocardial performance in fontan patients using udenafil compositions

The present invention relates to a topical composition and method of use, specifically an oil-in-water emulsion, comprised of sweet almond oil, lavender oil, rose oil, cinnamon bark oil, and coriander seed oil in a physiologically acceptable topical carrier. The composition is applied to a circumcised penis to enhance sensitivity, preferably twice daily for a time period of at least about two weeks. Thereafter a maintenance dose can be applied once a day to maintain a desired level of sensitivity.

Sensitization composition and method of use

The present invention relates to a topical composition and method of use, specifically an oil-in-water emulsion, comprised of sweet almond oil, lavender oil, rose oil, cinnamon bark oil, and coriander seed oil in a physiologically acceptable topical carrier. The composition is applied to a circumcised human penis to enhance sensitivity, preferably twice daily for a time period of at least about two weeks. Thereafter a maintenance dose can be applied once a day to maintain a desired level of sensitivity.

Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic Cto Calcohol, an aliphatic Cto Cester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.

Alprostadil and dyclonine for treatment of premature ejaculation

Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a vasoactive prostaglandin, a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic Cto Calcohol, an aliphatic Cto Cester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.

Alprostadil for treatment of premature ejaculation

Alprostadil and lidocaine treatment of premature ejaculation

Compositions and methods for treatment of premature ejaculation

A topical composition, specifically an oil-in-water emulsion, comprised of ketoprofen and oxybenzone in a physiologically acceptable topical carrier. The composition is applied topically to alleviate pain, especially pain associated with migraine headache. The composition has good photostability as well as freeze/thaw stability.

Topical ketoprofen composition

The invention provides methods and compositions for treating erectile dysfunction. The methods include the step of placing within the fossa navicularis of the patient an effective erection-inducing amount of a vasoactive prostaglandin composition of a semi-solid consistency. The composition comprises a vasoactive prostaglandin, a penetration enhancer, a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N-substituted amino)-alkanoate ester, a (N-substituted amino)-alkanol alkanoate, or a mixture of these enhancers. The lipophilic compound may be an aliphatic Cto Calcohol, aliphatic Cto Cester, an aliphatic Cto Cester, or a mixture of these. The composition includes a buffer system providing a buffered pH value for said composition in the range of about 3 to about 7.4.

Prostaglandin compositions and methods of treatment for male erectile dysfunction

The invention provides compositions and methods suitable for ameliorating female sexual dysfunction, and in particular, female sexual arousal disorder. In one embodiment, the invention provides a semisolid composition suitable for topical application comprising: an effective amount of a vasoactive prostaglandin, a polysaccharide thickener, a lipophilic component, and an acidic buffer system.

Growing community of inventors

Lake Forest, IL, United States of America

James L Yeager